235 related articles for article (PubMed ID: 12756509)
41. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
[TBL] [Abstract][Full Text] [Related]
42. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
43. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
[TBL] [Abstract][Full Text] [Related]
44. Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits.
Wang X; Lin Y; Luo N; Chen Z; Gu M; Wang J; Chen Y
Chin Med J (Engl); 2014; 127(16):2953-9. PubMed ID: 25131234
[TBL] [Abstract][Full Text] [Related]
45. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
46. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Undas A; Celinska-Löwenhoff M; Löwenhoff T; Szczeklik A
J Thromb Haemost; 2006 May; 4(5):1029-36. PubMed ID: 16689755
[TBL] [Abstract][Full Text] [Related]
47. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
48. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
49. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
50. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
[TBL] [Abstract][Full Text] [Related]
51. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Undas A; Celinska-Löwenhoff M; Domagala TB; Iwaniec T; Dropinski J; Löwenhoff T; Szczeklik A
Thromb Haemost; 2005 Jul; 94(1):193-9. PubMed ID: 16113803
[TBL] [Abstract][Full Text] [Related]
52. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
53. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
Krysiak R; Gdula-Dymek A; Okopien B
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):198-202. PubMed ID: 22935083
[TBL] [Abstract][Full Text] [Related]
54. [Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Zeman M; Vecka M; Stopka P; Zahin M; Tvrzická E; Stanková B; Vareka T; Janíková L; Zák A
Cas Lek Cesk; 2006; 145(12):923-8. PubMed ID: 17323614
[TBL] [Abstract][Full Text] [Related]
55. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
Alegret M; Verd JC; Díaz C; Hernández G; Adzet T; Sánchez RM; Laguna JC
Eur J Pharmacol; 1998 Apr; 347(2-3):283-91. PubMed ID: 9653895
[TBL] [Abstract][Full Text] [Related]
56. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
57. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Milionis HJ; Bairaktari ET; Liberopoulos EN; Elisaf MS
Am J Cardiol; 2001 Jul; 88(2):203. PubMed ID: 11463061
[No Abstract] [Full Text] [Related]
58. Development of an experimental diet model in rats to study hyperlipidemia and insulin resistance, markers for coronary heart disease.
Munshi RP; Joshi SG; Rane BN
Indian J Pharmacol; 2014; 46(3):270-6. PubMed ID: 24987172
[TBL] [Abstract][Full Text] [Related]
59. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
60. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
Flores-Castillo C; Zamora-Pérez JÁ; Carreón-Torres E; Arzola-Paniagua A; Aguilar-Salinas C; López-Olmos V; Fragoso JM; Luna-Luna M; Rodríguez-Pérez JM; Franco M; Vargas-Alarcón G; Pérez-Méndez Ó
Fundam Clin Pharmacol; 2015 Aug; 29(4):362-70. PubMed ID: 25982284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
